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Circulating levels of four adipokines (adiponectin, TNF-, leptin, and resistin) and the
postprandial lipid and adiponectin responses to an oral fat load were assessed in 25 non-
obese, non-diabetic patients with biopsy-proven nonalcoholic steatohepatitis (NASH) and
correlated with metabolic indices and liver histology. Circulating adiponectin was lower in
NASH compared with controls (5,476 344 vs. 11,548 836 ng/mL; P .00001) and on
multiple regression analysis correlated negatively with liver steatosis, necroinflammation
(OR  5.0; P  .009), and fibrosis (OR  8.0; P  .003).The magnitude of postprandial
lipemia was significantly higher in NASH than in controls and was related to fasting adi-
ponectin (  0.78; P  .00003). Controls showed a significant increase in serum adi-
ponectin in response to the fat load, whereas patients with NASH showed a slight decrease.
Postprandial free fatty acids response correlated inversely with adiponectin response in both
groups and independently predicted the severity of liver steatosis in NASH (  0.51; P
.031). In conclusion, hypoadiponectinemia is present before overt diabetes and obesity
appear and correlates with the severity of liver histology in NASH. Impaired postprandial
lipidmetabolismmay be an additional mechanism linking hypoadiponectinemia andNASH
and posing a higher cardiovascular risk to these subjects. Themechanism(s) underlying these
differences are unknown, but the type of dietary fat seems to play a role. These findings may
have important pathogenetic and therapeutic implications in both liver and metabolic dis-
ease. (HEPATOLOGY 2005;42:1175-1183.)
Nonalcoholic steatohepatitis (NASH) is a chronicliver disease encountered in individuals withoutsignificant alcohol consumption; it is part of a
spectrum of liver damage, ranging from simple steatosis to
advanced fibrosis and cirrhosis, named nonalcoholic fatty
liver disease (NAFLD). NAFLD is the most common
chronic liver disease, with a prevalence of 20% inWestern
populations,1 and is present from milder stages of the
metabolic syndrome until overt hyperglycemia and/or
obesity appear.2
Adipokines have been implicated in the pathogenesis
of type 2 diabetes mellitus and NAFLD, through their
metabolic and pro-/anti-inflammatory activity.3,4 Leptin
promotes insulin resistance and hepatic disease in cell cul-
tures and animal models through activation of the trans-
forming growth factor beta axis and stellate cells.5 Clinical
studies yielded controversial results in NAFLD, finding
either a link between leptin and steatosis6 or no direct
association between leptin and liver disease.7,8 Adiponec-
tin and tumor necrosis factor alpha (TNF-) have been
recently related to hepatic steatosis and inflammation, but
not to fibrosis, in NASH.4
Resistin is another adipose tissue–derived cytokine
linking adiposity and insulin resistance in animal models,
but data from subjects with NAFLD are lacking.9,10
Impaired postprandial triglyceride (Tg) metabolism is
a marker of increased cardiovascular risk11 and may pro-
mote hepatic steatosis via an increased uptake of Tg-rich
lipoproteins and free fatty acids (FFA) from the blood
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and/or a reduced hepatic secretion of apoB100-contain-
ing lipoproteins.12
Adiponectin has been recently linked to lipid metabo-
lism, being able to predict fasting Tg and high-density
lipoprotein (HDL) cholesterol levels independently of in-
sulin sensitivity and visceral obesity,13 but data on its re-
lation with Tg and FFA metabolism in the postprandial
phase are sparse.
Aims of this study were to assess the association of four
adipose tissue–derived cytokines (i.e., adiponectin,
TNF-, leptin, and resistin) with the severity of liver dis-
ease and to provide a dynamic assessment of the relations
between circulating adiponectin and lipid metabolism in
non-obese non-diabetic patients with biopsy-proven
NASH.
Patients and Methods
Patient Selection. Twenty-five patients (mean age
SEM, 37 2 years; body mass index [BMI], 25.3 0.2
kg/m2) attending our Liver Unit were selected according
to the following criteria: persistently (at least 12 months)
elevated aminotransferases; ultrasonographic presence of
bright liver without any other liver or biliary tract disease;
liver histology compatible with a diagnosis of NASH (ste-
atosis involving al least 5% of hepatocytes, presence of
lobular inflammation and zone 3 ballooning degenera-
tion14). Exclusion criteria were: a history of alcohol con-
sumption 40 g/wk , as assessed by a detailed interview
extended to familymembers and general practitioners and
by a validated questionnaire filled in daily for 1 week by
the patients; a BMI 30 kg/m2 for men and 28 for
women; positive serum markers of viral, autoimmune, or
celiac disease; abnormal copper metabolism or thyroid
function tests; a diagnosis of overt diabetes mellitus (fast-
ing plasma glucose 126 mg/dL or 200 mg/dL at 2
hours on a standard oral glucose load, OGTT); serum
total cholesterol200 mg/dL; serum triglycerides200
mg/dL; exposure to occupational hepatotoxins or drugs
known to be steatogenic or to affect glucose metabolism.
Mutations in the hemochromatosis genesHFE andTRF2
were detected in patients and controls using multiplex
amplification reaction (Nuclear Laser Medicine, Milan,
Italy).
Liver iron concentration was determined on 2 mg dry
weight tissue by atomic absorption spectroscopy. The he-
patic iron index was obtained dividing liver iron concen-
tration (mol/g) by age (years; normal range below 0.5).
The controls consisted of 25 healthy subjects matched
for age, sex, BMI, percent body fat, waist circumference,
and waist-to-hip ratio with normal liver enzymes and ab-
domen ultrasound scan (Table 1).
Patients and controls gave their consent to the study,
which was conducted according to the Helsinki Declara-
tion.
Alimentary Record. Patients and controls were in-
structed to fill in a 7-day diet record during a 30-minute
individual session with a trained nutritionist; a list of
foods was designed, and for each item different portion
sizes were specified according to the EPIC study.15 The
recorded period included a complete week, and the record
was collected within 1week of the tolerance tests. The diet
record was analyzed using the WinFood database (Medi-
matica, TETeramo, Italy) according to the table of food
consumption of the Italian National Institute of Nutri-
tion16 and Food CompositionDatabase for Epidemiolog-
ical Study in Italy.17
Anthropometric Measurements. Percent body fat
was determined by the bioelectric impedance method
Table 1. Baseline Characteristics of Patients With NASH
and Controls
NASH
(n  25)
Controls
(n  25) P
Age (yr) 37 2 38 2 .725
Sex (M/F) 23/2 23/2 .999
Family history of type 2 diabetes
(no. patients) 3 2 .760
Smokers (no. patients) 3 4 .999
BMI (kg/m2) 25.3 0.2 25.2 0.6 .884
Body fat (%) 23 2 22 4 .824
Waist (cm) 90 2 87 2 .294
Waist/hips ratio 0.92 0.01 0.91 0.05 .865
Abdominal visceral fat area (cm2) 90 5 84 6 .345
Systolic blood pressure (mm Hg) 129 2 126 3 .784
Diastolic blood pressure (mmHg) 88 1 77 1 .0002
Triglycerides (mg/dL)* 97 9 78 6 .144
Total cholesterol (mg/dL)† 177 10 169 6 .471
HDL cholesterol (mg/dL)† 48 2 58 3 .018
LDL cholesterol (mg/dL)† 110 10 102 5 .454
FFA (mmol/L) 0.66 0.04 0.46 0.03 .006
Uric acid (mg/dL)‡ 6.19 0.29 5.19 0.26 .022
Glucose (mg/dL) 97 2 86 2 .019
Insulin (U/mL) 19.6 2.1 7.3 1.1 .001
Albumin (g/dL) 4.7 0.1 5.0 0.1 .312
AST (U/L) 41 3 26 3 .021
ALT (U/L) 87 7 30 4 .0001
GGT (U/L) 89 18 41 4 .006
ALP (U/L) 86 8 52 7 .011
HFE mutation (H63D) heterozygotes
(no. subjects) 4 3 .367
Serum iron (g/dL) 99 4 91 4 .346
Ferritin (g/L) 168 21 135 20 .227
Transferrin (% sat) 32 1 29 3 .131
NOTE. Data are presented as mean  SEM.
Abbreviations: LDL, low-density lipoprotein; AST, aspartate aminotransferase;
ALT, alanine aminotransferase; GGT, gamma glutamyltransferase; ALP, alkaline
phosphatase.
*To convert mg/dL to mmol/L, multiply by 0.01129.
†To convert mg/dL to mmol/L, multiply by 0.02586.
‡To convert mg/dL to mol/L, multiply by 59.48.
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(TBF-202, Tanita, Tokyo, Japan), whose measures
closely correlate with those obtained by dual X ray absorp-
tion.18
Abdominal visceral fat area (cm2) was estimated using
the equations developed by Stanforth et al., validated
against computed tomography in Caucasians19
Cytokine Measurements. Serum TNF-, leptin, and
adiponectin (both low- and high-molecular-weight
forms) were measured by sandwich ELISA (R&D System
Europe Ltd, Abingdon, UK). Resistin was measured by a
biotin-labeled antibody–based sandwich enzyme immu-
noassay (Bio Vendor Laboratori Medicine, Inc., Brno,
Czech Republic).
Oral Glucose Tolerance Test. After completion of
the alimentary record, patients and controls underwent a
standard 75-g OGTT; samples for plasma glucose and
serum insulin were drawn at 0, 30, 60,90, and
120 minutes. The whole-body and hepatic insulin sen-
sitivity indices (ISI) were assessed from the OGTT, as
previously described.20
Oral Fat Load. Patients and controls underwent an
oral fat load test, as previously described,21 within 7 days
of the OGTT. Participants were encouraged to avoid
strenuous physical efforts and to follow their usual diet
during the 24 hours preceding the test. The fat load con-
sisted of amixture of 200 g dairy cream (35% fat) and 26 g
egg yolk for a total energy content of 766 kcal.: 78.3 g fat
(55.6% saturated fatty acids, 29.6% monounsaturated
fatty acids, 14.8% polyunsaturated fatty acids), 595 mg
cholesterol, 8.8 g protein, 7 g carbohydrate. The fat load
was consumed during a period of 5 minutes; subjects kept
fasting on the test morning, and strenuous activity was
forbidden, because exercise can reduce postprandial li-
pemia. Samples were drawn at 0 (baseline), 2, 4, 6, 8, and
10 hours. Plasma total cholesterol (Chol), Tg, and FFA
were measured by automated enzymatic methods. Very-
low-density lipoproteins (VLDL) were isolated through
preparative ultracentrifugation and assayed for their Tg
and total Chol content. Apo E genotype was determined
by polymerase chain reaction amplification of genomic
DNA using specific oligonucleotide primers.
Statistical Analysis. Data were expressed as mean 
SEM. Differences were considered statistically significant
at P less than .05. Differences between groups were ana-
lyzed by ANOVA when variables were normally distrib-
uted; otherwise, the Mann-Whitney test was used.
Normality was evaluated by Shapiro-Wilk test. Chi-
square test or Fisher’s exact test were used to compare
categorical variables.
Data from the oral fat load and from the OGTT were
compared by ANOVA and Scheffe` post hoc test after loga-
rithmic normalization of skewed variables. Differences in
mean adiponectin values between the different patient sub-
groups of the metabolic syndrome were analyzed by
ANOVA followed by Student-Neuman-Keuls test.
The area under the curve (AUC) and incremental area
under the curve AUC (IAUC; computed on the area ex-
ceeding baseline) of plasma total Tg, VLDL-Tg, FFA, and
adiponectin during the oral fat loadwere computed by the
trapezoid method. Simple and multiple regression analy-
ses were used to estimate linear relationship between dif-
ferent clinical, dietary, and biochemical continuos
variables, after log transformation of skewed data.
Multiple logistic regression analysis was used to iden-
tify independent predictors for advanced necroinflamma-
tion (grade 3) or fibrosis (stage 3). The covariates for these
analyses were age, BMI, waist circumference, waist-to-hip
ratio, fasting insulin and cytokine levels, and ISI.
Results
Baseline Parameters. Baseline features of NASH pa-
tients and controls are reported in Table 1. Patients had
higher mean diastolic pressure, fasting plasma glucose,
FFA, and serum insulin and lower HDL-cholesterol than
controls.
According to ATP III criteria,22 eighteen patients had
hypertension (systolic/diastolic blood pressure 130/85
mm Hg), four were hypertriglyceridemic (fasting plasma
triglycerides 150 mg/dL), seven had low plasma HDL
cholesterol (HDL-C40mg/dL inmen and50mg/dL
in women), eight had impaired glucose regulation (two
had impaired fasting glycemia, that is, fasting plasma glu-
cose 100 mg/dL but 126 mg/dL, and six had im-
paired glucose tolerance, that is, plasma glucose140 but
200 mg/dL at 2 hours on OGTT), and three had
abdominal obesity (waist circumference102 cm inmen
and 88 cm in women). Seven patients had the whole
picture of the metabolic syndrome (three or more criteria
met), eleven met two criteria, and seven met only one
criterion.
Cytokines. Serum adiponectin levels were signifi-
cantly lower in patients with NASH than in controls,
whereas no difference was found in levels of the other
cytokines (Table 2).
Histopathology. Fatty infiltration was mild (involv-
ing 5%-33% of hepatocytes) in eight patients, moderate
(33%-66% of hepatocytes) in nine subjects, and severe
(66% of hepatocytes involved) in eight patients. Necro-
inflammatory activity was grade 1 in nine patients, grade
2 in nine, and grade 3 in seven. Fibrosis was stage 0 in
seven patients, 1 in five patients, 2 in five patients, and 3
in eight patients; changes in cirrhosis were absent in our
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patients. Liver iron concentration was 17 3mol/g dry
weight, and hepatic iron index was 0.51 0.04.
Alimentary Record. Daily energy and macronutrient
intake did not differ in the 2 groups: 2,582 123 versus
2,498  168 kcal, P  .888; carbohydrate, 52%  2%
vs. 50% 2% kcal, P .591; protein, 15% 1% versus
16% 2 % kcal, P .716; fat, 33% 1% versus 34%
 1% kcal, P .482. Compared with controls, patients
consumed a diet richer in saturated and poorer in poly-
unsaturated fat, expressed both as percentage of total cal-
ories and percentage of total fat intake21: saturated fatty
acids (SFA), 12.1%  0.6% versus 10.0%  0.6% tot
kcal, P .009; polyunsaturated fatty acids (PUFA), 3.9%
 0.2% versus 5.1%  0.2% tot kcal, P  .002. Poly-
unsaturated to saturated fat ratio was also significantly
lower in the NASH group (P/S ratio: 0.31  0.03 vs.
0.44 0.04, P .0001),as well as daily intake of vitamin
E (5.0 0.4 vs. 7.2 0.5 mg, P  .0007)
Oral Glucose Tolerance Test. No patient had diabe-
tes, six had impaired glucose tolerance, two had impaired
fasting glycemia, and the others had a normal glucose
regulation (fasting plasma glucose100 mg/dL).
The whole body and hepatic ISI were significantly
lower in the NASH group than in controls: whole body
ISI: 3.40 1.83 versus 7.81 0.87; P .0003; hepatic
ISI: 0.37 0.25 versus 1.31 0.18; P  .0001.
Oral Fat Tolerance Test. No significant difference
was seen in Apo E allelic frequency: 13 patients with
NASH and 11 controls were E3/E3, 8 patients with
NASH and nine controls were E4/E3, and four patients
with NASH and five controls were E3/E2.
Postprandial plasma total Tg and VLDL-Tg responses
are reported in Fig. 1. Plasma total and VLDL Tg were
significantly higher in the group with NASH at all times
except at 0 hours (P .05 at2 and8 hours; P .005
at4,6, and10 hours).
Plasma AUC-Tg and IAUC-Tg were significantly
higher in patients with NASH compared with controls
(AUC-Tg: 1,281  127 vs. 904  57 mg/dL  hour,
P  .01; IAUC-Tg: 368  66 vs. 130  53 mg/dL 
hour; P  .004). VLDL-Tg AUC was higher in patients
with NASH than in the controls (1,046 101 vs. 701
94 mg/mL hour; P .01), as well as VLDL-Tg IAUC
(464 65 vs. 237 40 mg/mL hr; P  .004).
Postprandial FFA response is reported in Fig. 1C:
plasma FFA levels were higher in NASH than in controls
Fig. 1. Oral fat load test. Data are presented as mean  SEM. Star,
P  .05 vs. controls. Rhombus, P  .005 vs. controls. Plus sign, P 
.05 vs basal values.
Table 2. Circulating Cytokine Values in Patients With NASH
and Controls
NASH
(n  25)
Controls
(n  25) P
TNF- (pg/mL) 1.18 0.11 0.99 0.04 .111
Adiponectin (ng/mL) 5,476 344 11,548 836 .00001
Leptin (pg/mL) 2,108 789 2,518 678 .695
Resistin (ng/mL) 4.12 0.37 4.28 0.21 .709
NOTE. Data are presented as mean  SEM.
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at all times (P  .001); AUC-FFA was higher in NASH
than in controls (11.2  1.5 vs. 6.4  0.3 mmol/L 
hour; P  .003) as well as IAUC-FFA (4.3  0.9 vs.
1.7 0.4 mmol/L hour; P  .006).
Postprandial adiponectin response is reported in
Fig. 1D: in NASH, adiponectin levels were lower than
in controls all through the test (P .00001 at all times)
and slightly decreased postprandially, reaching statisti-
cal significance compared with baseline at 8 hours
and 10 hours (4,842  340 vs. 6223  479 ng/mL,
P  .023), whereas in controls they rose postprandi-
ally, reaching statistical significance compared with
baseline at 6 hours (15,149  1091 vs. 11,432 
948 ng/mL, P  .014).
IAUC-adiponectin was also significantly lower in
NASH compared with controls: 6,493  2,998 vs.
12,547 5,388 ng/mL hour; P  .002.
Plasma glucose and serum insulin levels did not change
through the test (not shown)
Correlations Between Anthropometric, Metabolic,
and Histological Parameters. ISI correlated with waist
circumference (r0.43; P .010), serum adiponectin
(r 0.64; P .00003), TNF- (r0.56; P .0005)
and SFA intake, expressed both as percent energy (r 
0.50; P  .003) and as percent fat intake (r  0.49;
P  .004) On multiple regression analysis, only SFA in-
take expressed as percent energy (F  10;   0.54;
P .0003) and adiponectin levels ( 0.43; P .002)
independently predicted ISI.
Hepatic ISI correlated with waist circumference (r 
0.45; P  .007), serum adiponectin (r  0.49; P 
.003), serum TNF- (r  0.42; P  .011), plasma
triglyceride (r0.44; P .008), andHDL-cholesterol
(r  0.40; P  .016). On multiple regression analysis,
only waist circumference (F 7; 0.53; P .002)
and serum adiponectin levels (  0.40; P  .01) pre-
dicted hepatic ISI.
IAUC-Tg correlated with basal adiponectin levels (r
0.82; P .00002; Fig 2), with IAUC-adiponectin (r
0.62; P .001), with IAUC-FFA (r 0.49; P .003),
and with HDL-cholesterol (r  0.49; P  .003). On
multiple regression analysis, only basal adiponectin (F
20;   0.78; P  .00003) and IAUC-adiponectin
(0.40; P .037) independently predicted IAUC-
Tg.
IAUC-VLDL Tg correlated with basal adiponectin
(r  0.71; P  .0008), with IAUC-adiponectin (r 
0.60; P  .002) and with HDL-cholesterol (r 
0.61; P .0018).Onmultiple regression analysis, basal
adiponectin (F 18;0.68; P .0001) and IAUC-
adiponectin (  0.40; P  .009) independently pre-
dicted log IAUC-VLDL Tg.
IAUC-FFA correlated with IAUC-adiponectin (r 
0.58; P  .002), insulin sensitivity index (r  0.40;
P  .020) and IAUC-Tg (r  0.49; P  .003). On
multiple regression analysis, only IAUC-adiponectin
(F  4.43;   0.44; P  .041) and IAUC-Tg ( 
0.33; P  .040) predicted IAUC-FFA.
Fasting adiponectin correlated with whole body and
hepatic ISI (see earlier discussion), with IAUC-Tg (see
earlier discussion), with PUFA intake expressed as percent
energy (r  0.60; P  .001) , with P/S ratio (r  0.42;
P .037), with HDL-C (r 0.42; P .037), and with
fasting insulin (r  0.47; P  .017). On multiple re-
gression analysis (adiponectin as the outcome variable),
only IAUC-Tg (F  10.4;   0.70; P  .0007) and
PUFA intake (  0.40; P  .041) independently pre-
dicted fasting adiponectin levels.
In both groups (only NASH correlation coefficients
reported), IAUC-adiponectin correlated with IAUC-Tg
(r  0.58; P  .005), IAUC-FFA (r  0.46; P 
.030), ISI (r 0.47; P .029), and hepatic ISI (r 0.48;
P  .026). On multiple regression analysis, only
IAUC-Tg predicted postprandial adiponectin increase in
both patients and controls (in NASH, F 5;0.50;
P  .011).
Serum leptin levels correlated with BMI (r 0.42;P
.011) and with percent body fat (r  0.49; P  .0029),
but with no other variable.
In patients with NASH, hepatic steatosis correlated
with fasting adiponectin (r  0.64; P  .0006),
IAUC-Tg (r  0.51; P  .008), IAUC-FFA (r  0.61;
P .001), and waist circumference (r 0.43; P .048).
On multiple regression analysis (steatosis as the outcome
variable), only fasting adiponectin (F  5;   0.55;
P  .011) and IAUC-FFA (  0.51; P  .031) pre-
dicted the severity of steatosis.
On logistic regression analysis, hypoadiponectinemia
predicted severe necroinflammation and fibrosis stage 3
even after controlling for the effect of age, BMI, ISI, waist
circumference, and the other cytokines (Tables 3, 4).
Fig. 2. Correlation between postprandial IAUC-Tg and fasting adi-
ponectin levels (log transformed; r: Pearson correlation coefficient).
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Discussion
The main contributions of this work are that it (1)
demonstrates the association of low serum adiponectin
levels with the severity of liver histology in biopsy-proven
NASH; (2) correlates the magnitude of postprandial li-
pemia to circulating adiponectin and to the severity of
hepatic steatosis; and (3) documents a dynamic adiponec-
tin response to an oral fat load, which was strikingly dif-
ferent between healthy subjects and patients with NASH
and was related to postprandial FFA response.
The role of circulating adipokines in the pathogenesis
of NAFLD remains controversial,4,6,8 because their levels
are related to body fat mass and may simply reflect the
association between NALFD and other risk factors for
liver disease (i.e., overall or central obesity or diabetes),
rather than a true causal relationship. Furthermore, dif-
ferent cytokines may intervene as metabolic syndrome
and hepatic inflammation progress: the adipokines al-
tered in diabetes, obesity, and cirrhosis thus may not be
the same that switched the whole metabolic and inflam-
matory cascade. We therefore selected non-obese non-
diabetic patients with varying severities of metabolic
syndrome and liver histology.
Previous studies correlated hypoadiponectinemia to
hepatic fat content, and adiponectin delivery alleviated
steatosis and LPS-induced liver injury in animal fatty
liver, through modulation of TNF- and peroxisome
proliferator-activated receptor- activity.23
Our study further expands the protective role of adi-
ponectin to liver necroinflammation and fibrosis: signifi-
cantly lower adiponectin levels were in fact present in
advanced fibrosis, despite a similar degree of insulin resis-
tance and visceral fat accumulation. Recently, Hui et al.4
found that hypoadiponectinemia and insulin resistance
independently predicted the severity of steatosis and
necroinflammation, but not of fibrosis, in NAFLD with
central adiposity distribution.4 The discrepancy between
these two studies deserves comment: unlike steatosis and
necroinflammation, which can vary over a short period in
relation to lifestyle changes (i.e., diet, physical activity,
hormonal status), progression of fibrosis may occur over a
much longer period in NASH. Plasma adipokine levels
fluctuate over time, depending on the metabolic milieu,
as well. Cross-sectional measurements of cytokines there-
fore may variably correlate with the severity of hepatic
fibrosis, depending on the time the measure is made. The
finding that changes in severity of steatosis and inflamma-
tion run an independent course from those of fibrosis has
been previously reported.24
Consistently with our data, adiponectin attenuated
carbon tetrachloride–induced liver fibrosis in mouse
models.25 The suppressive effect of adiponectin on plate-
let-derived growth factor– and transforming growth fac-
tor-1–induced proliferation and migration of cultured
hepatic stellate cells provides the molecular basis for the
anti-fibrotic effect of this adipokine.25
These observations point to hypoadiponectinemia as
the specific marker of NASH and support the hypothesis
that adipokines may underlie both the metabolic milieu
that causes liver fat accumulation and precipitate the
necroinflammatory and fibrotic responses in NASH.
In keeping with previous studies, most of our patients
were males1,2; a likely explanation is that the physiologi-
cally lower adiponectin levels seen in men may render
their liver more susceptible to harmful factors such as
visceral fat–released free fatty acids, TNF-, and possibly
dietary factors. Postprandial lipid and adiponectin re-
sponses to an oral fat load were also assessed in our study.
The absence of carbohydrate in the test meal was designed
to prevent the significant postprandial glucose and insulin
increase elicited by mixed meals used in other studies.26-28
The ability of insulin to suppress human adiponectin gene
expression29 and the release of FFA and to enhance tri-
glyceride catabolism may in fact affect postprandial lipid
and adiponectin responses.30
The higher postprandial lipid response observed in our
patients could play a role in liver Tg accumulation, as the
magnitude of FFA increase correlated significantly with
the severity of hepatic steatosis. In healthy subjects, 36%
of lipoprotein lipase–generated FFA escape peripheral
storage in adipose tissue and muscle and are available for
liver uptake,31 and this figure may be even higher in insu-
lin-resistant subjects. Donnelly et al.32 demonstrated in
obese NAFLD subjects that the liver usage of different
Table 4. Multiple Ordinal Regression Analysis for Factors
Associated With Fibrosis Stage 3 in Patients With NASH
Factor OR 95% CI P
Age (per 6-year increase) 0.5 0.1-1.9 .27
BMI (per 2-kg/m2 increase) 4.1 0.4-40.1 .20
Waist (per 3-cm increase) 0.6 0.2-4.3 .46
ISI (per unit increase) 1.3 0.3-5.7 .75
Adiponectin (per 1,000-ng/mL decrease) 8.0 1.5-81 .003
Table 3. Multiple Ordinal Regression Analysis for
Factors Associated With Necroinflammatory Grade 3 in
Patients With NASH
Factor OR 95% CI P
Age (per 6-year increase) 0.9 0.3-2.1 .69
BMI (per 2 kg/m2 increase) 1.5 0.4-6.9 .72
Waist (per 3-cm increase) 0.8 0.3-1.9 .59
ISI (per unit increase) 1.9 0.6-5.9 .23
Adiponectin (per 1,000-ng/mL decrease) 5.0 1.1-28.1 .009
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sources (adipose tissue vs. dietary fat) of plasma FFA var-
ies widely from fasting to feeding conditions, resulting in
changes of up to 60% of the FFA used for Tg synthesis. In
particular, postprandial dietary FFA spill-over contrib-
uted substantially to liver and VLDL Tg synthesis, and
this contribution is even larger as dietary fat intake in-
creases.33
Interestingly, basal adiponectin levels independently
predicted the postprandial triglyceride increase in our pa-
tients. This finding may be explained by the ability of this
adipokine to enhance Tg-rich lipoprotein catabolism and
FFA oxidation. Exogenous adiponectin in fact enhanced
fatty acid oxidation by activating adenosine monophos-
phate–activated protein kinase and to acutely reduce the
postprandial FFA increase in mice.34,35 Tg-rich lipopro-
tein catabolism also may be affected: hypoadiponectine-
mia independently predicted postheparin lipoprotein
lipase activity in diabetic and nondiabetic patients, ac-
counting for 25% of the variation in lipoprotein lipase
activity in these subjects.36 Furthermore, kinetic studies
point to adiponectin as an important regulator of VLDL-
apoB catabolism, independently of other adipokines or
insulin resistance indices.37
An intriguing finding was the striking difference in
adiponectin response to the fat challenge between the two
groups: controls showed a prompt postprandial increase
in circulating adiponectin, which rose up by 35% above
basal levels, peaking at 6 hours, whereas NASH patients
showed no increase but rather a slight decrease in its levels,
reaching statistical significance at 8 and 10 hours
(25% compared with basal values). Consistently, post-
prandial IAUC-adiponectin was also significantly lower
in NASH patients than in controls.
In both groups, postprandial adiponectin response cor-
related inversely with the magnitude of postprandial FFA
increase.
Although further studies are required to elucidate the
meaning of this observation, postprandial lipemia physi-
ologically evokes an acute “compensatory” increase in adi-
ponectin secretion aiming at restoring baseline plasma
lipid levels by enhancing FFA oxidation and Tg-rich li-
poprotein catabolism in target tissues. Consistently with
this model, intravenous infusion of lipid emulsions was
associated with a small but significant increase in adi-
ponectin levels at 6 hours and, conversely, pharmacolog-
ical lowering of circulating FFA levels conveyed a
significant decrease in adiponectin levels in healthy sub-
jects.38,39
The failure of this compensatory mechanism inNASH
may contribute substantially to liver steatosis and to he-
patic and peripheral insulin resistance.
Alternatively, postprandial lipid metabolism may be
primarily impaired inNASH and promote Tg storing and
oxidative stress (which is increased in our patients; un-
published data) in hepatocytes and visceral adipocytes,
eventually leading to hepatic steatosis and impaired adi-
ponectin secretion.40,41 If this were the case, the reduction
of postprandial lipemia and of oxidative stress would be a
primary therapeutic target in patients with NASH, even
in the absence of overt obesity or diabetes.
Our findings agree with part, but not all, of the litera-
ture. Peake et al.26 found no difference in adiponectin
response to a mixed meal between normal and insulin-
resistant subjects over a 6-hour period; however, basal
adiponectin values were similar in the two groups, and the
mixed meal elicited a significant insulin rise.26 Vuppalan-
chi et al.27 found no difference in adiponectin response to
amixedmeal betweenNASHpatients and controls after 3
hours. It is possible that the abundance of adiponectin in
blood, as compared with any other adipokines, and its
long half-life (2.5-6 hours) may have masked any acute
regulatory action of lipid load over the short term in pre-
vious studies.
By contrast, English et al.28 found a 4-fold postpran-
dial increase in adiponectin levels after a mixed meal in
obese subjects, with an early steep rise at 1 hour and a
plateau lasting 1 hour.
The mechanism(s) responsible for hypoadiponectine-
mia and for the lack of the physiological increase in
NASH are unknown. A genetic background may be in-
volved: in a recent French prospective study, variations at
the adiponectin locus affected body weight gain, body fat
distribution, and onset of hyperglycemia, as well as adi-
ponectin levels, over a 3-year period.3
Among acquired factors, chronic hyperinsulinemia
and diet may play a role. In hyperinsulinemic euglycemic
clamp studies, in fact, insulin infusion provoked a pro-
longed inhibition on adiponectin gene expression and cir-
culating levels in lean and obese subjects.42,43
Our patients consumed a diet richer in saturated and
poorer in polyunsaturated fat compared with controls,
and PUFA intake independently predicted fasting adi-
ponectin levels. Available data show that the amount and
type of dietary fat regulate adiponectin secretion by acting
on nuclear sterol regulatory element-binding protein
1c44 : a 3-day low-fat diet increased circulating adiponec-
tin without affecting insulin levels or insulin sensitivity in
diabetic patients.45 The addition of different amounts of
PUFA increased adipose tissue mRNA and plasma adi-
ponectin and decreased liver lipogenic enzymes and fat
content in different mouse models.46,47
In healthy humans, dietary saturated fat intake corre-
lated negatively with circulating adiponectin, whereas
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omega-3 fatty acids were positively associated with this
adipokine.48
In conclusion, we confirmed that hypoadiponectine-
mia is an early finding in NASH, being detectable long
before overt diabetes and overall or central obesity appear,
and which correlates with the severity of liver histology.
We provided evidence of an additionalmechanism poten-
tially linking adiponectin and NASH, postprandial lipid
metabolism, and found a strikingly different postprandial
adiponectin response between our patients and healthy
controls, which may promote liver fat accumulation and
insulin resistance in NASH.
Our data should prompt future research to focus on
lipid metabolism in addition to insulin resistance, given
the implications for both liver and cardiovascular disease
in these subjects. This study has obvious limitations re-
lated to its cross-sectional nature, which prevents any
causal inference from the associations we found, and to
the prevalence of male sex in our patients, which suggests
caution when extending our results to women.
Acknowledgment: The authors thank Dr. E. David
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